Medical Writing Public Disclosure An interview with Chris Winchester
volume27-issue2png

Volume 27, Issue 2 - Public Disclosure

An interview with Chris Winchester

Abstract

Chief Executive Officer of HealthScience communications consultancy Oxford PharmaGenesis and a leading member of Open Pharma

References

  1. Winchester C. AMWA-EMWA-ISMPP Joint Position Statement on the Role of Professional Medical Writers. Med Writ. 2017;26(1):7–8.
  2. Baronikova S, Purvis J, Winchester C, Southam E, Beeso J, Panayi A. Disclosure of Results of Clinical Trials Sponsored By Pharmaceutical Companies; Presented at the 8th International Congress on Peer Review and Scientific Publication, Chicago, September 10–12, 2017.
  3. FDAAA Trials Tracker. 2018 [cited 2018 Apr 27]. Available from Available from: http://fdaaa.trialstracker.net/
  4. Gattrell WT, Hopewell S, Young K, Farrow P, White R, Wager E, et al. Professional medical writing support and the quality of randomised controlled trial reporting: a cross-sectional study. BMJ Open. 2016;6(2):e010329.
  5. Mills I, Sheard C, Hays M, Douglas K, Winchester C, Gattrell WT. Professional medical writing support and the reporting quality of randomized controlled trial abstracts among high-impact general medical journals; F1000Research. 2017;6:1489.
  6. Evuarherhe O, Gattrell WT, White R, Winchester C. Association between professional medical writing support and the quality, ethics and timeliness of clinical trials reporting: a systematic review. Curr Med Res Opin. 2018;34(Suppl 1):30 [poster 2]. Presented at the 2018 European Meeting of the International Society of Medical Publication Professionals (ISMPP, London, 23–24 January 2018). Available form: Available from: www.healthsciencelive.com/713932
  7. Desai S, D’Angelo G, Panayi A, Baronikova S, Carter G, Evuarherhe O, et al. Involvement of medical writers in the development of health economic and outcomes research publications in inflammatory bowel disease – a systematic literature review. Curr Med Res Opin. 2017;33(Suppl 1):14 [poster 19]. Presented at the 2017 European Meeting of the International Society of Medical Publication Professionals (ISMPP, London, 17–18 January 2017). Available from: Available from: http://www.healthsciencelive.com/UK/121679

Search

Articles

Editorial
President’s Message
EMWA News
The Regulatory Public Disclosure Special Interest Group
Clinical trial disclosure and transparency
Clarity and Openness in Reporting: E3-based (CORE) Reference
Navigating the EMA clinical data website
Anonymisation reports from 2016 to 2017: A preliminary analysis
Preparing anonymisation reports in general and for an orphan drug in particular
Policies 0070 and 0043: Juggling different requirements
Clinical data publication by the EMA: The challenges facing the pharmaceutical industry
Clinical trial results disclosure on ClinicalTrials.gov and EudraCT
Writing lay summaries: What medical writers need to know
Lay titles for clinical trials: A balancing act
Why clinical study reports really matter
CORE Reference – a tool for modern clinical study reports in an era of increasing transparency and disclosure
Preparing clinical study reports for external sharing
Harmonising format and style requirements for scientific and medical publications
News from the EMA
Winners of the Geoff Hall Scholarship Essay Competition
Creative medical writing: An oxymoron?
Creative medical writing - An oxymoron?
An interview with Chris Winchester
Journal Watch
In the Bookstores
Good Writing Practice
Medical Devices
Getting Your Foot in the Door
Out on Our Own
Upcoming issues ofMedical Writing

Member Login

Links

The Write Stuff Archive Contact Instructions for Authors Feature Article Template (Word) Journal Policies

Editoral Board

Editor-in-Chief:

Co-Editor:

Managing Editor

show all +

Associate Editors:

Section Editors:

Ad-hoc Editors:

  • Amy Whereat (SpeaktheSpeech Consulting, Asnieres sur Seine, France)

Editor Emeritus: